Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
58.47
+1.19 (2.07%)
May 4, 2026, 10:53 AM EDT - Market open
Spruce Biosciences Employees
Spruce Biosciences had 8 employees as of December 31, 2025. The number of employees decreased by 13 or -61.90% compared to the previous year.
Employees
8
Change
-13
Growth
-61.90%
Revenue / Employee
n/a
Profits / Employee
-$4,870,750
Market Cap
158.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -13 | -61.90% |
| Sep 30, 2025 | 9 | -13 | -59.09% |
| Jun 30, 2025 | 9 | -13 | -59.09% |
| Mar 31, 2025 | 20 | -2 | -9.09% |
| Dec 31, 2024 | 21 | -8 | -27.59% |
| Sep 30, 2024 | 22 | -9 | -29.03% |
| Jun 30, 2024 | 22 | -10 | -31.25% |
| Mar 31, 2024 | 22 | -8 | -26.67% |
| Dec 31, 2023 | 29 | 2 | 7.41% |
| Sep 30, 2023 | 31 | 9 | 40.91% |
| Jun 30, 2023 | 32 | 15 | 88.24% |
| Mar 31, 2023 | 30 | 14 | 87.50% |
| Dec 31, 2022 | 27 | 12 | 80.00% |
| Sep 30, 2022 | 22 | 3 | 15.79% |
| Jun 30, 2022 | 17 | -4 | -19.05% |
| Mar 31, 2022 | 16 | -3 | -15.79% |
| Dec 31, 2021 | 15 | -2 | -11.76% |
| Sep 30, 2021 | 19 | 4 | 26.67% |
| Jun 30, 2021 | 21 | 6 | 40.00% |
| Mar 31, 2021 | 19 | 4 | 26.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Molecular Partners AG | 134 |
| Alps Group | 93 |
| Agenus | 81 |
| Tenaya Therapeutics | 70 |
| InflaRx | 65 |
| TuHURA Biosciences | 22 |
| Black Diamond Therapeutics | 21 |
| Edesa Biotech | 17 |
SPRB News
- 3 hours ago - Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations - Business Wire
- 13 days ago - Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 13 days ago - Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 7 weeks ago - Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates - Business Wire
- 2 months ago - Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer - Business Wire
- 2 months ago - Spruce Biosciences to Present at Upcoming Investor Conferences in March - Business Wire